Screener
Kymera Therapeutics KYMR Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income (expense): | ||||
| Interest and other income | 14,477 | 8,051 | 29,459 | 16,968 |
| Interest and other expense | (81) | (108) | (141) | (180) |
| Total other income: | 14,396 | 7,943 | 29,318 | 16,788 |
| Net loss | $(61,211) | $(76,614) | $(130,445) | $(142,195) |
| Other comprehensive loss: | ||||
| Unrealized (loss) gain on marketable securities | (2,963) | 337 | (8,957) | 1,764 |
| Total comprehensive loss | $(64,174) | $(76,277) | $(139,402) | $(140,431) |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's other income, net (note 6)?
- Kymera Therapeutics (KYMR) reported other income, net (note 6) of $14.4M in Q2 2026.
- How has Kymera Therapeutics's other income, net (note 6) changed year-over-year?
- Kymera Therapeutics's other income, net (note 6) increased by 81.2% year-over-year, from $7.94M to $14.4M.
- What is the long-term trend for Kymera Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), Kymera Therapeutics's other income, net (note 6) has grown at a 232.0% compound annual growth rate (CAGR), from $313K to $38.05M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Kymera Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude